These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 19150121)

  • 1. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.
    Fulham MJ; Carter J; Baldey A; Hicks RJ; Ramshaw JE; Gibson M
    Gynecol Oncol; 2009 Mar; 112(3):462-8. PubMed ID: 19150121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
    Rustin GJ; van der Burg ME; Griffin CL; Guthrie D; Lamont A; Jayson GC; Kristensen G; Mediola C; Coens C; Qian W; Parmar MK; Swart AM; ;
    Lancet; 2010 Oct; 376(9747):1155-63. PubMed ID: 20888993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
    Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; de Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E
    J Clin Oncol; 2014 May; 32(13):1309-16. PubMed ID: 24687829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
    Prat J;
    Int J Gynaecol Obstet; 2014 Jan; 124(1):1-5. PubMed ID: 24219974
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
    Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
    Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of Peritoneal Metastases in Ovarian Cancer Using MDCT, MRI, and FDG PET/CT: A Systematic Review and Meta-Analysis.
    Tsili AC; Alexiou G; Tzoumpa M; Siempis T; Argyropoulou MI
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Positron Emission Tomography/Computed Tomography in Epithelial Ovarian Cancer.
    Chandra R; Kumari S; Bhatla N; Kumar R; Tiwari A; Sachani H; Kumar L
    Indian J Nucl Med; 2023; 38(4):366-375. PubMed ID: 38390547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.
    Allahqoli L; Hakimi S; Laganà AS; Momenimovahed Z; Mazidimoradi A; Rahmani A; Fallahi A; Salehiniya H; Ghiasvand MM; Alkatout I
    J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
    Nunes RL; Teixeira FR; Diniz TP; Faloppa CC; Mantoan H; da Costa AABA; Baiocchi G
    J Gynecol Oncol; 2023 May; 34(3):e31. PubMed ID: 36731894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.
    Virarkar M; Ganeshan D; Gulati AT; Palmquist S; Iyer R; Bhosale P
    Abdom Radiol (NY); 2021 Jun; 46(6):2323-2349. PubMed ID: 33175199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study.
    Gu B; Xia L; Ge H; Liu S
    Quant Imaging Med Surg; 2020 Mar; 10(3):743-753. PubMed ID: 32269933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of
    Cengiz A; Koç ZP; Özcan Kara P; Yürekli Y
    Mol Imaging Radionucl Ther; 2019 Mar; 28(1):8-14. PubMed ID: 30942056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's New in Imaging for Gynecologic Cancer?
    Khan SR; Arshad M; Wallitt K; Stewart V; Bharwani N; Barwick TD
    Curr Oncol Rep; 2017 Nov; 19(12):85. PubMed ID: 29105030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the role of PET/CT and PET/MRI in ovarian cancer.
    Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Werner TJ; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1079-1091. PubMed ID: 28180966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttreatment FDG PET/CT in predicting survival of patients with ovarian carcinoma.
    Chu LC; Tsai HL; Wang H; Crandall J; Javadi MS; Wahl RL
    EJNMMI Res; 2016 Dec; 6(1):42. PubMed ID: 27206785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.
    Evangelista L; Palma MD; Gregianin M; Nardin M; Roma A; Nicoletto MO; Nardelli GB; Zagonel V
    J Turk Ger Gynecol Assoc; 2015; 16(3):137-44. PubMed ID: 26401105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.
    Rusu D; Carlier T; Colombié M; Goulon D; Fleury V; Rousseau N; Berton-Rigaud D; Jaffre I; Kraeber-Bodéré F; Campion L; Rousseau C
    Front Med (Lausanne); 2015; 2():46. PubMed ID: 26258124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
    Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
    Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.